Displaying drugs 7451 - 7475 of 8178 in total
Cemdomespib
Cemdomespib is under investigation in clinical trial NCT05895552 (A Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS)).
Investigational
Matched Description: … Cemdomespib is under investigation in clinical trial NCT05895552 (A Phase 2 Study of RTA 901 in Patients …
Darigabat
Darigabat is under investigation in clinical trial NCT05941442 (A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder).
Investigational
Matched Description: … investigation in clinical trial NCT05941442 (A Study to Evaluate Efficacy, Safety, and Tolerability of …
Dihydroxyacetone
A ketotriose compound. Its addition to blood preservation solutions results in better maintenance of 2,3-diphosphoglycerate levels during storage. It is readily phosphorylated to dihydroxyacetone phosphate by triokinase in erythrocytes. In combination with naphthoquinones it acts as a sunscreening agent. [PubChem]
Experimental
Matched Description: … Its addition to blood preservation solutions results in better maintenance of 2,3-diphosphoglycerate …
105AD7
105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55, overexpressed by many solid tumours including osteosarcoma. 105AD7 induced antitumour inflammatory responses in metastatic colorectal cancer patients. 105AD7 may be a suitable vaccine for treatment of this disease.
Investigational
Matched Description: … responses in metastatic colorectal cancer patients. 105AD7 may be a suitable vaccine for treatment of …
AME-527
AME-527 is a humanized monoclonal antibody that recognizes human TNF-alpha (hTNF-alpha) with high affinity and specificity. AME-527 was generated by protein engineering and identified from a library of antibody variants based on its improved binding properties.
Investigational
Matched Description: … AME-527 was generated by protein engineering and identified from a library of antibody variants based …
Autologous Non-Hematopoietic Peripheral Blood Stem Cells
Autologous non-hematopoietic peripheral blood stem cells have been created into a formulation for use in a clinical trial (NCT04473170) by the Abu Dhabi Stem Cells Center. The cells have the characterizations of CD90+, CD133+, Oct-4+, CD45-, and CD71-.
Investigational
Matched Description: … The cells have the characterizations of CD90+, CD133+, Oct-4+, CD45-, and CD71-.[L16363] …
Vibostolimab
Vibostolimab is under investigation in clinical trial NCT04303169 (Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)).
Investigational
Matched Description: … Vibostolimab is under investigation in clinical trial NCT04303169 (Substudy 02C: Safety and Efficacy of …
NN344
NN344 is a neutral, soluble long-acting human insulin analogue with 24 hour coverage by once daily injection. NN344 has a very flat and predictable action profile. The product is intended for basal insulin treatment of diabetes mellitus.
Investigational
Matched Description: … The product is intended for basal insulin treatment of diabetes mellitus. …
Lobeline
An alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent. It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation. [PubChem]
Investigational
Matched Description: … It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral …
PI-166
PI-166 is a small organic compound with specific avidity to liver cancer cells. It has demonstrated the ability to reduce the growth of rat hepatomas, which is like human hepatomas, are resistant to established anti-cancer agents.
Investigational
Matched Description: … It has demonstrated the ability to reduce the growth of rat hepatomas, which is like human hepatomas, …
IRL-1620
SPI-1620 is an endothelin B receptor agonist. In animal models SPI-1620 selectively and transiently increases tumor blood flow allowing increased delivery of anticancer agents to the tumor. It is being developed as an adjunct to chemotherapy.
Investigational
Matched Description: … models SPI-1620 selectively and transiently increases tumor blood flow allowing increased delivery of …
Muplestim
Muplestim is under investigation in clinical trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia).
Investigational
Matched Description: … trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of …
Azintuxizumab vedotin
Azintuxizumab vedotin is under investigation in clinical trial NCT02951117 (A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment).
Investigational
Matched Description: … Azintuxizumab vedotin is under investigation in clinical trial NCT02951117 (A Study of Venetoclax and …
TMC-649128
TMC-649128 is under investigation in clinical trial NCT01391117 (TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin).
Investigational
Matched Description: … Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of …
Amlitelimab
Amlitelimab is under investigation in clinical trial NCT06181435 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)).
Investigational
Matched Description: … Amlitelimab is under investigation in clinical trial NCT06181435 (A Study to Evaluate the Efficacy and Safety of …
Ohmefentanyl
Ohmefentanyl is an extremely potent opioid analgesic drug which selectively binds to the µ-opioid receptor. The Chinese have recorded ohmefentanyl as having a potency that is 6,300 times morphine. Ohmefentanyl is one of the most potent μ -receptor agonists known, comparable to super-potent opioids such as carfentanil and etorphine which...
Illicit
Matched Description: … Researchers are studying the different pharmaceutical properties of these isomers. ... Ohmefentanyl is one of the most potent μ -receptor agonists known, comparable to super-potent opioids …
LY2140023
LY2140023 is an investigational drug from Lilly, which is being developed as a new treatment option for schizophrenia. LY2140023 is an oral "prodrug," meaning it is devoid of intrinsic biological activity and, once administered, is metabolized to provide the active mGlu2/3 receptor agonist called LY404039. Most currently approved antipsychotic medications...
Investigational
Matched Description: … LY2140023 is an oral "prodrug," meaning it is devoid of intrinsic biological activity and, once administered ... For LY2140023, the active substance, LY404039, is thought to work by reducing the presynaptic release of …
D-Lactic acid
A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
Experimental
Matched Description: … A normal intermediate in the fermentation (oxidation, metabolism) of sugar. …
Daglutril
Daglutril is an orally active, mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development for the treatment of essential hypertension and congestive heart failure.
Investigational
Matched Description: … mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development for the treatment of …
MLN2222
MLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of the complement activation pathway.
Investigational
Matched Description: … proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of …
Rivoglitazone
Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.
Experimental
Investigational
Matched Description: … Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes …
Buparlisib
Buparlisib has been used in trials studying the treatment and basic science of Lymphoma, Metastases, Lung Cancer, Solid Tumors, and Breast Cancer, among others.
Investigational
Matched Description: … Buparlisib has been used in trials studying the treatment and basic science of Lymphoma, Metastases, …
Peficitinib
Peficitinib has been used in trials studying the treatment and basic science of Psoriasis, Pharmacodynamics, Drug Interactions, Colitis, Ulcerative, and RHEUMATOID ARTHRITIS, among others.
Investigational
Matched Description: … Peficitinib has been used in trials studying the treatment and basic science of Psoriasis, Pharmacodynamics …
Ralimetinib
Ralimetinib has been used in trials studying the treatment of Postmenopausal, Advanced Cancer, Adult Glioblastoma, Fallopian Tube Cancer, and Metastatic Breast Cancer, among others.
Investigational
Matched Description: … Ralimetinib has been used in trials studying the treatment of Postmenopausal, Advanced Cancer, Adult …
Osugacestat
Osugacestat (BMS-906024) has been used in trials studying the treatment of Cancer, Lymphoblastic Leukemia, Acute T-cell, and Precursor T-Cell Lymphoblastic Lymphoma.
Investigational
Matched Description: … Osugacestat (BMS-906024) has been used in trials studying the treatment of Cancer, Lymphoblastic Leukemia …
Displaying drugs 7451 - 7475 of 8178 in total